Country Roundtable — Mexico, Colombia, Peru
Mexico, Colombia, and Peru represent three of Latin America’s most compelling growth markets in clinical research. Mexico and Colombia share large, diverse, and largely treatment-naïve populations with high patient motivation, and both have regulatory bodies — COFEPRIS and INVIMA, respectively — actively modernizing to reduce approval timelines and increase predictability. Peru adds a distinct dimension: a highly diverse patient population, a steadily strengthening regulatory authority in DIGEMID, and growing Phase 2–3 opportunity that is placing the country on sponsor shortlists as a high-value complement to more established markets. Together, these countries represent a reform-driven, population-rich corridor with significant upside for sites positioned to capitalize on it.
